RIGL Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 35.57%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 37.67%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 53.56%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.007% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.08x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.44x versus 4.98x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ironwood Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 32.84%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 37.67%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -29.63%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.007% more volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.483%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.08x while Ironwood Pharmaceuticals, Inc.'s PE ratio is 29.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.44x versus 2.24x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -301.29%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Nektar Therapeutics's return on equity of -327.67%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 37.67%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 203.69%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.007% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.08x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.44x versus 38.85x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 34.76%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 37.67%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $500.40 which suggests that it could grow by 13.38%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.110, which suggesting that the stock is 11.007% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.08x while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.44x versus 9.75x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.